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Pluripotencywas conﬁrmed both in vivo and in vitro. The transcriptome proﬁle of epiHUVEC and the human em-
bryonic stem cell line— H1 have a Pearson correlation of 0.899.
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Human umbilical vein endothelial cells (HUVECs) were re-
programmed by nucleofection of oriP/EBNA1 (Epstein–Barr nuclearrch and Regenerative Medicine,
dorf, Germany.
icle under the CC BY-NC-ND licenseantigen-1)-based episomal vectors which express the reprogramming
factors OCT4, SOX2, NANOG, LIN28, KLF4 and c-MYC and were treated
with three small molecules PD0325901 (inhibitor of MEK), SB431245
(inhibitor of TGFβ) and CHIR99021 (inhibitor of GSK3β) (Prigione
et al., 2010; Wang & Adjaye, 2011). After 12 passages the iPSC-line
epiHUVEC had completely lost the episomal vectors as shown by PCR.
epiHUVEC expresses the pluripotency associated transcription factors
OCT4, NANOG, SOX2 and cell surface markers SSEA-4, TRA-l-60, and
TRA-1-81. The pluripotency was further demonstrated in vitro by
embryoid body-based differentiation to cell types representative
of the three germ layers endoderm, ectoderm and mesoderm and
in vivo by teratoma formation in immunodeﬁcient mice. Chromosomal
analysis revealed a normal and female karyotype. In addition, a dendro-
gram represents the similarity of the iPSC transcriptome proﬁle to that
of human embryonic stem cell line (H1) with a Pearson correlation of
R2 = 0.899.
3. Materials and methods
3.1. Cell culture
The HUVECs were bought from Life Technologies (Gibco; C-003-5C)
and were cultured in Medium 200 (Gibco/Life Technologies) with
2% Low Serum Growth Supplement (LSGS; Gibco/Life Technologies) at
37 °C and 5% CO2 in an incubator (INNOVA CO-170 Incubator, New
Brunswick Scientiﬁc) under humidiﬁed atmosphere. The induced plu-
ripotent stem cell (iPSC) line was cultured on Matrigel-coated plates
with mitotic inactivated mouse embryonic ﬁbroblast (MEF) cells and
an unconditioned medium (UM). UM consist of KnockOut DMEM
(Gibco/Life Technologies) supplemented with 20% Knock-Out Serum
Replacement (Gibco/Life Technologies), 0.1 mM non-essential amino
acids (Invitrogen/Life Technologies), 0.1 mM L-glutamine (Invitrogen/(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Characterization of the iPSC line epiHUVEC.A) Immunoﬂuorescence-based detection of humanpluripotent speciﬁc proteinsOCT4, SOX2,NANOGand surfacemarker SSEA-4, TRA-1-
60 and TRA-1-81 as well as the absence of the differentiation marker SSEA-1 in the iPSC line. DAPI stained the nucleus (blue). Scale bar: 200 μm Alexa Flour 594 (red), Alexa Fluor 488
(green). B) All three germ layers mesoderm, ectoderm and endoderm were detected in vitro by formation of embryoid bodies. Immunochemistry was performed for ectoderm protein
Nestin (NES), endoderm protein α-Fetoprotein (AFP) and mesoderm protein Brachyury (T). DAPI stained the nucleus (blue). Scale bar: 200 μm, Alexa Flour 594 (red), Alexa Fluor 488
(green). C) Teratoma formation of E-iPSCs. 1: Ectoderm, 2: Endoderm; 3: Mesoderm. D) Presence of a female karyogram 46,XX. E) Dendogram of HUVEC, HUVEC-derived iPSC and
hESC. F) Vector loss detection in iPSCs at passage 12. Detection of: 1) EBNA-1; 2) OriP; 3) LIN28; 4) SV40LT; 5) NANOG; 6) OCT4 and 7) human genome gene sequence of OCT4.
100 bp marker was used. The vectors which were transfected were used as positive controls, H2O and the original cell line HUVEC as negative controls.
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penicillin and streptomycin and 8 ng/ml basic ﬁbroblast growth factor
(bFGF, Invitrogen/Life Technologies) (Prigione et al., 2010; Wang &
Adjaye, 2011).3.2. Derivation of iPSCs
To generate vector-free iPSCs three oriP/EBNA1 (Epstein–Barr nucle-
ar antigen-1)-based episomal vectors published by Yu et al., (2011)
were used. These vectors express the reprogramming factors OCT4,
SOX2, NANOG, KLF4, LIN28, c-MYC and SV40LT. A nucleofection was
done by using a cell-speciﬁc Amaxa Cell Line Nucleofector Kit (Lonza)
and one single electroporationwas sufﬁcient. 2.5 × 105 of the cells of in-
terest were used. The cells were centrifuged and then diluted in 100 μl
Nucleofection Solution which contained the vector DNA. The amount
of plasmids used for one nucleofection was 3.0 μg of pEP4EO2SEN2K,
3.0 μg of pEP4EO2SET2K and 2.0 μg of pCEP4-M2L as described by Yu
et al., (2011). The transfected cells were seeded on a Matrigel-coated
6-well-plate containing the same medium the cells were cultured be-
fore the nucleofection. One day after nucleofection the cells were treat-
ed with the following small molecules; A TGFβ-inhibitor (SB431245,
Sigma, in a concentration of 2 μM), a MEK inhibitor (PD0325901,
Sigma, in a concentration of 1 μM) and a GSK3β-inhibitor (CHIR99021,
Sigma, in a concentration of 0.5 μM). Three weeks later colonies with
ES-like morphology were picked and expanded further.3.3. Polymerase Chain Reaction
PCR reactions were used to detect the presence or absence of the
plasmids. The PCR was carried out using a Thermocycler type PTC100
(MJ Research Inc.) for 32 cycles and each cycle contained 94 °C for
15 s, 58 °C for 30 s and 68 °C for 1 min. Primer sequences are as de-
scribed by Yu et al. (2011).
3.4. Embryoid body formation
hESCs or iPSCs were seeded on ultra-low attachment dishes
(Corning) and cultured in DMEM (Gibco/Life Technologies). The cells
formed spheres, so called embryoid bodies (EBs). These EBs were cul-
tured for seven days and then seeded onto 12 well cell culture dishes
previously coated with 0.1% gelatin. The EBs attached onto the gelatin
surface and differentiated for further 10 days. Thereafter, they were
ﬁxedwith 4% paraformaldehyde and germ layer speciﬁcmarker protein
visualization was carried out by immunoﬂuorescence-based staining.
3.5. Immunoﬂuorescence-based detection of proteins
The cells were ﬁxed with 4% paraformaldehyde for 20min at RT and
washed two timeswith PBS. Subsequently, the cells were permeabilized
with 0.1% Triton X-100 in PBS for 10 min. Next the cells were blocked
with a solution consisting of 10% fetal bovine serum (Invitrogen), 0.1%
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were washed with PBS two times for 5 min at RT. The primary antibody
was diluted in 10% fetal bovine serum (Invitrogen), 0.1% Triton X-100
in PBS. The cells were covered with primary antibody solution (1:200)
and left on for 1 h at RT. Primary antibodies were used as follows:
OCT4 (Santa Cruz, #sc-5279), NANOG (R&D, #AF1997), and SOX2
(Santa Cruz, #sc-17320). Antibodies against SSEA4, TRA-1-60
and TRA-1-81 of the hESC characterization kit (Merck Millipore,
#SCR004) were used. In addition, antibodies were used against
Smooth-Muscle-Actin (SMA) (Dako, #M0851), α-Fetoprotein (AFP)
(Sigma, #WH0000174M1), SOX17 (R&D, #AF1924), PAX6 (Covance,
#PRB-278P), NESTIN (Chemicon, #MAB5326), β-TubulinIII (TUJ1)
(Sigma, #T8660), and Brachyury (T) (R&D, #AF2085). The cells were
washed twice with PBS for 5 min at RT. The secondary antibody against
the species in which the ﬁrst antibodywas produced, was diluted 1:300
in 10% fetal bovine serum (Invitrogen), 0.1% Triton X-100 in PBS. The
secondary antibody was either conjugated to the dye Alexa Fluor 488
(Invitrogen, #A11055) for green ﬂuorescence or to Alexa Fluor 594
(Invitrogen, #A21468) for red ﬂuorescence. The diluted secondary anti-
body solution was added to the cells using the same volume like for the
primary antibody and was left on the cells for 1 h at RT in the dark
followed by two washing steps with PBS for 5 min at RT. The nuclei of
the cells were counterstained with 4′,6-Diamidin-2-phenylindol
(DAPI, 200 ng/ml, Invitrogen, #H3570). The ﬂuorophores on the sec-
ondary antibodies were visualized using a Zeiss, LSM 510Meta confocal
microscope with a connected camera for microscopy model AxioCam
ICc3 and the software Axiovision 4.6.
3.6. Teratoma formation
The in vivo differentiation experiments (teratoma formation) were
performed by EPO Berlin GmbH (Germany, http://www.epo-berlin.
de). Approximately 2 × 106 cells of the cell line were harvested by
combined type IV collagenase treatment and 0.05% Trypsin/EDTA-
treatment and washed. Cells were resuspended in 50 μl PBS, then
mixed with Matrigel (1:2) and immediately injected subcutaneously
into NOD.Cg-rkdcscid Il2rgtm1Wjl/SzJ mice, commonly known as NOD
scid gamma (NSG). Teratoma formation was carefully monitored andmice sacriﬁced 63 days after injection. The teratomas were collected
and processed using standard procedures for parafﬁn embedding,
then hematoxylin and eosin staining. Histological analysis was per-
formed by a Pathologist.
3.7. Karyotype analysis
Chromosomal analysis was performed after GTG-banding by Prof.
Dr. G. Thiel (Praxis für Humangenetik, Friedrichstr. 147, 10117 Berlin,
Germany). 20 metaphases were counted and 6 karyograms analyzed.
3.8. RNA-based microarray analysis
Total RNA was isolated for each sample. For global gene expression
analysis on an Illumina microarray platform quality-checked total
RNA was used. 500 ng RNA for each sample was used as input for the
ampliﬁcation and biotin labeling reactions (Illumina TotalPrep RNA
Ampliﬁcation Kit, Ambion, Austin, TX, USA), which precede bead
chip hybridizations. The cRNA synthesis, BeadChip hybridization and
scanning were performed by ATLAS Biolabs GmbH (http://www.
atlasbiolabs.com). The dendrogram compares the expression data and
the correlation values were calculated using the Gene Expression Mod-
ule of the software GenomeStudio (Illumina).
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